Compile Data Set for Download or QSAR
maximum 50k data
Found 5700 with Last Name = 'babu' and Initial = 'ys'
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM50579244(Avoralstat | BCX-4161)
Affinity DataKi:  0.260nMAssay Description:Inhibition of purified human plasma kallikrein assessed as inhibition constant using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by m...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416926((+)-1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl...)
Affinity DataKi:  0.440nMAssay Description:Inhibition of purified human plasma kallikrein assessed as inhibition constant using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by m...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase(Escherichia coli (strain K12))
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50183258(2-amino-4-[5-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7...)
Affinity DataKi:  1.70nMAssay Description:Inhibition of Escherichia coli MTANMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeuraminidase(Influenza B virus (B/Lee/40))
University Of Alabama At Birmingham

Curated by ChEMBL
LigandPNGBDBM4707(3-(2,2-diaminoimino)-4-methylcarboxamidobenzoate |...)
Affinity DataKi:  2.5nMAssay Description:In vitro inhibitory activity of the compound against B/Lee/40 Influenza B Neuraminidase.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPurine nucleoside phosphorylase(Mus musculus)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50039549(3-(2-Amino-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyri...)
Affinity DataKi:  5nMAssay Description:Binding affinity against Purine nucleoside Phosphorylase from calf spleenMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPurine nucleoside phosphorylase(Homo sapiens (Human))
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50033666(2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methox...)
Affinity DataKi:  8.70nMAssay Description:Inhibition of Purine nucleoside Phosphorylase from calf spleen at 1 mM PO4More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPurine nucleoside phosphorylase(Homo sapiens (Human))
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50033666(2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methox...)
Affinity DataKi:  8.70nMAssay Description:Binding affinity against hydrophobic pocket of Purine nucleoside PhosphorylaseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPurine nucleoside phosphorylase(Homo sapiens (Human))
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50033666(2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methox...)
Affinity DataKi:  8.70nMAssay Description:Inhibition of Purine nucleoside Phosphorylase from calf spleen at 1 mM PO4More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPurine nucleoside phosphorylase(Bos taurus (bovine))
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50046234(2-Amino-7-benzyl-3,4a,5,7a-tetrahydro-pyrrolo[3,2-...)
Affinity DataKi:  12nMAssay Description:Inhibition of purine nucleoside phosphorylase against the enzyme from calf spleen in 1 mM phosphateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPurine nucleoside phosphorylase(Bos taurus (bovine))
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50046239(2-Amino-9-thiophen-3-ylmethyl-1,9-dihydro-purin-6-...)
Affinity DataKi:  15nMAssay Description:Inhibition of Purine nucleoside phosphorylase was evaluated against the enzyme from calf spleen in 1 mM phosphateMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM474862(US10849883, Compound 279a | US11559515, Compound 2...)
Affinity DataKi:  19nMAssay Description:Inhibition of human complement factor D using Z-L-Lys-SBzl hydrochloride as substrate preincubated for 15 mins followed by substrate addition and mea...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416751(Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416757(1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-(1...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416760((E/Z)-1-(3-(Aminomethyl)phenyl)-N-(3-(3-cyclopropy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416763(1-(3-(Aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416764(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416766(1-(3-(aminomethyl)phenyl)-N-(3-((2-cyclopropyletho...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416767(1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-hy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416770(Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416773(1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416774(1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-hy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416775(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416777(1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416779(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416780(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416782(1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416783(2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416784(1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416785(1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416786(2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416787(1-(3-(aminomethyl)phenyl)-N-(3-cyclopropyl-5-((cyc...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416788(1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416789(1-(3-(aminomethyl)phenyl)-N-(5-((4-aminophenyl)(cy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416790(1-(3-(Aminomethyl)phenyl)-N-(2-chloro-5-((cyclopro...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416791(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416792(1-(3-(aminomethyl)phenyl)-N-(5-((3-aminophenyl)(cy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416794(Racemic 1-(3-(aminomethyl)phenyl)-N-(5-((cycloprop...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416795(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416796(1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416797(1-(3-(aminomethyl)phenyl)-N-(5-fluoro-2-methyl-1,2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416798(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416799(2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416975((+-)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-2-yl)p...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416977((+-)-N-(5-(1-acetamido-3-cyclopropyl-1-(pyridin-3-...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416975((+-)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-2-yl)p...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM610052((+)-1-(3-(aminomethyl)phenyl)-5-(5-((cyclopropyl m...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416980((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416981((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-3-yl)pr...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416983((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM416981((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-3-yl)pr...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 5700 total ) | Next | Last >>
Jump to: